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ABSTRACT  
 
Epidemiological studies have shown that arsenic exposure during early 
embryogenesis can cause reduced weight gain and neurological deficits later on in life. In 
addition, in vitro and in vivo studies have indicated that arsenic suppresses neurogenesis 
and myogenesis. The exact mechanism of how arsenic causes these undesired 
developmental outcomes is poorly understood, however both skeletal muscle and sensory 
neuron development require the Wnt/β-catenin signaling pathway to initiate the specific 
differentiation of precursor cells. We were interested in determining the target cell 
population of arsenic and its metabolites.  Arsenic’s metabolites were of interest because 
they have been shown to be more toxic than arsenic itself.   
We found that arsenic and its metabolites, monomethylarsonous (MMA III) acid 
and dimethylarsinous (DMA III) acid, target a specific population of progenitor cells 
termed the neural plate border specifier (NPBS) cells by reducing the expression of 
signals required for neurogenesis (Pax3, Sox10, and NeuroD1) and myogenesis (Msx1, 
MyoD, and Myogenin).  Pluripotent P19 embryonic stem cells were differentiated into 
embryoid bodies (EBs) in the presence of 0.1μM and 0.5μM sodium arsenite, 0.01μM 
and 0.05μM MMA III, or 0.001μM and 0.005μM DMA III. The expression of myogenic 
and neurogenic signals was determined by immunohistochemistry in EBs after 2-5 days 
of differentiation. Starting on day 2, in the neurogenic pathway, and day 3 in the 
myogenic pathway, arsenic is targeting the neural plate border specifier (NPBS) cells, 
which resulted in reduced transcription factor expression of Pax3 and Msx1. Arsenic also 
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altered nuclear localization of Msx1 (day 2), MyoD (days 2-5), NeuroD1 (days 4-5), and 
altered co-localization patterns in both the neurogenic and myogenic lineages.  
After exposure to arsenic’s metabolites, MMA III and DMA III, more drastic 
patterns were seen. In the neurogenic pathway, it appears that MMA III is targeting the 
neural plate border specifier cells on day 3, while DMA III does not affect transcription 
factor expression until day 5. Co-localization patterns were again changed after exposure. 
After 3 days of MMA III and DMA III exposure, co-localization patterns were 
significantly changed in the myogenic pathway. In regards to nuclear localization 
MyoD’s nuclear localization was significantly decreased on days 3 and 5 in both the 
MMA and DMA treatments. In the neurogenic pathway, NeuroD1’s nuclear localization 
was significantly decreased in day 5 EBs after exposure to both MMA and DMA. 
Overall, these results suggest that arsenic and its metabolites are targeting the 
precursor cells to skeletal muscles and sensory neurons, and are therefore suppressing 
neurogenesis and myogenesis. 
  
 iv 
DEDICATION 
 
 
To my family and most importantly my mother, Dyanna Lynn McCoy, who is and 
always will be my source of inspiration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 v 
ACKNOWLEDGMENTS  
I would like to say thank you to my family, friends, and co-workers who helped 
me in every aspect of this thesis. Without your guidance and help this work would have 
never been completed. To my advisor, Dr. Lisa Bain, who I can’t thank enough for her 
expertise, knowledge, and encouragement during my time in her lab. To the members of 
my committee, Dr. Charles Rice and Dr. David Feliciano for their guidance and 
knowledge during this process. To John Cummings, who I worked for as a teaching 
assistant during my time at Clemson, whose support and advice played was much needed 
and always appreciated. Also, thank you to Bradley S. Stadelman, and Julia L. 
Brumaghim of the Dept. of Chemistry at Clemson for their work in synthesizing the 
arsenic metabolites that were such an integral part to my work. 
To my mom, Dyanna, your support these past seven and half years throughout my 
soccer and graduate school career have been unwavering. Your trust in me knowing what 
I was doing, even when I didn’t, gave me the encouragement to keep going when I 
wanted to quit. You taught me to never stop what you have started, and whatever 
obstacles are placed in front of you in life, to just keep going. 
To the past and present members of the Bain lab, your help and advice was 
second to none. To Ray, who taught me everything I know about cell culture and IHC. I 
would have never completed my experiments without his knowledge and willingness to 
help me when I had no idea to what I was doing. This work was truly a team effort and I 
can’t thank all of you enough. 
 
 
  
 vi 
TABLE OF CONTENTS 
 
 
Page 
 
TITLE PAGE .................................................................................................................... i 
 
ABSTRACT ..................................................................................................................... ii 
 
DEDICATION ................................................................................................................ iv 
 
ACKNOWLEDGMENTS ............................................................................................... v 
 
LIST OF TABLES ........................................................................................................ viii 
 
LIST OF FIGURES ........................................................................................................ ix 
 
CHAPTER 
 
 I. LITERATURE REVIEW .............................................................................. 1 
 
   Arsenic Sources and Location ................................................................. 1 
 
   Adverse Health Effects ............................................................................ 3  
 
   Developmental Health Effects of Arsenic ............................................... 4 
 
   P19 Cells .................................................................................................. 7 
 
   Neural Plate Border Specifier Cells ......................................................... 8 
 
   Methylated Arsenic Species  .................................................................... 9 
 
   Thesis Goals and Objectives .................................................................. 10 
 
   References  ............................................................................................. 12 
 
 
 
 II. ARSENIC TARGETS NEURAL PLAYE BORDER SPECIFIER CELLS IN 
P19 CELLS ............................................................................................ 18 
 
   Title Page ............................................................................................... 18 
 
  
 vii 
Table of Contents (Continued)                                                                                     Page 
 
   Abstract .................................................................................................. 19 
 
   Introduction ............................................................................................ 21 
   
Materials and Methods.............................................................................25 
P19 cell culture and differentiation of embryoid bodies............25 
Synthesis of MMA (III) and DMA (III).........................................26 
In situ synthesis of SO2.................................................................27 
Embryoid body exposure to MMA (III) and DMA (III)................27 
Immunohistochemistry..................................................................28 
Analysis of protein expression......................................................29 
Statistical analysis........................................................................29 
 
Results.......................................................................................................30 
Time course of transcription factor expression............................30 
Arsenic targets neural plate border specifier cells.......................31 
Monomethylarsonous acid (MMA III) and dimethylarsinous  
acid (III) targets neural plate border specifier cells.......32 
Arsenic alters nuclear localization of transcription factors........33 
Monomethylarsonous acid (MMA III) and dimethylarsinous 
acid (III) alters nuclear localization of transcription 
factors….............................................................................33 
Arsenic alters co-localization patterns………...............................34 
Monomethylarsonous acid (MMA III) and dimethylarsinous  
acid (III) alters co-localization patterns...........................35 
 
 
   Discussion ........................................................................................... ...35 
 
   References .............................................................................................. 64 
 
  
 
 III. CONCLUSION ............................................................................................ 71 
 
 
   References .............................................................................................. 74 
  
 viii 
LIST OF TABLES 
 
 
Table                                                                                                                               Page 
 
 1 Time course of transcription factor expression and nuclear translocation in 
P19 cell-derived embryoid bodies ......................................................... 54 
 
 2 Changes in overall transcription factor expression after exposure to 0.01 and 
0.5µM arsenic during p19 cell differentiation ....................................... 55 
 
 3 Changes in the nuclear translocation of transcription factors after exposure to 
0.01 and 0.5µM arsenic during p19 cell differentiation ........................ 56 
 
 4 Changes in overall transcription factor expression after exposure to 
monomethylarsonous acid (MMA) and dimethylarsinous acid (DMA) 
during p19 cell differentiation ............................................................... 57 
 
 5 Changes in the nuclear translocation of transcription factors after exposure to 
monomethylarsonous acid (MMA) and dimethylarsinous acid during p19 
cell differentiation .................................................................................. 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 ix 
LIST OF FIGURES 
 
 
Figure                                                                                                                             Page 
 
 1 Arsenic decreases pax3 intensity, and msx1 and myod nuclear localization in 
day 2 embryoid bodies ........................................................................... 42 
 
 2 Arsenic decreases sox10 intensity, and myod nuclear localization in day 3 
embryoid bodies ..................................................................................... 44 
 
 3 Arsenic decreases neurod1 intensity, and myod and neurod1 nuclear 
localization in day 4 embryoid bodies ................................................... 46 
 
 4 Arsenic decreases neurod1 intensity and nuclear localization in day 5 
embryoid bodies ..................................................................................... 48 
 
 5 MMA (III) decreases myod and pax3 nuclear localization in day 3 embryoid 
bodies ..................................................................................................... 50 
 
 6 MMA (III) decreases myod and pax3 nuclear localization in day 5 embryoid 
bodies ..................................................................................................... 51 
 
 7 DMA (III) decreases myod nuclear localization in day 3 embryoid bodies.52 
 
 8 DMA (III) decreases myod and neurod1 nuclear localization in day 5 
embryoid bodies ..................................................................................... 53 
 
 S1 MMA (III) decreases Msx1, MyoD, Pax3, Sox10 intensity in day 3  
   embryoid bodies  .................................................................................... 59 
 
 S2 MMA (III) decreases Pax3, Sox10 and NeuroD1 intensity in day 5 embryoid 
bodies ..................................................................................................... 60 
 
 S3 DMA(III) caused no marked decreases in transcription factor intensity 
    in day 3 embryoid bodies. ..................................................................... 61 
 
 S4 DMA(III) decreases Msx1, MyoD, Myogenin, Sox10 and NeuroD1 intensity 
in day 5 embryoid bodies. ...................................................................... 62 
 
  S5 Differentiating P19 cells contain Arsenic methyltransferase.......................63 
 
 
 
1 
CHAPTER ONE 
 
LITERATURE REVIEW 
 
  
Arsenic Sources and Location 
Arsenic is naturally occurring element that can be found in water, soil, and rocks. 
Arsenic also has no odor, tasteless, and colorless (Ambrosio et al., 2014) giving it the 
potential to be very dangerous.  Even though it is natural, it is a known carcinogen and 
toxicant that is posing many threats to human health. It is the 53
rd
 most abundant element 
on Earth, and varies in concentration from 1 ppm to 10 ppm in soil, and between 1.5-1.6 
ppm in seawater (Nickson et al., 2000). However, arsenic contamination in our 
environment, especially groundwater, has become a worldwide concern and is becoming 
an epidemic in many developing countries. It has been such an issue that the World 
Health Organization (WHO) has put arsenic on its list of the top 10 chemicals of major 
health concern (WHO).  
Even though arsenic is not found in a huge abundance in earth’s crust (Wedepohl, 
1995) it is easily solubilized by ground water (Smedley and Kinniburgh, 2002) making it 
very easy for arsenic contaminate drinking water. Anthropogenic arsenic contamination 
is very common due to arsenic’s historical use in pesticides, mineral extraction, smelting, 
and extraction of fossil fuels (Edelstein, 1985). It has also been used in recent times for 
industrial, medicinal, and homicidal purposes (Ambrosio et al., 2014). 
In the past few decades, it has been estimated that over 140 million people 
worldwide have arsenic in their drinking water and food sources, with over 4 million of 
those individuals living in the United States (Ambrosio et al., 2014).  In 2013, the U.S. 
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Food and Drug Administration found that common beverages such as beer could have on 
average 2.1 µg/serving (serving: 8 fl oz) of inorganic arsenic, and found that some brands 
of brown rice contain levels of 160 ppb of arsenic (FDA, 2013). What is also interesting 
to note is that what many consider to be a healthier option in brown rice, had much higher 
levels of arsenic than did the white instant rice brands (FDA, 2013). 
 In many parts of the world, a big reason for arsenic’s contamination of drinking 
water, which is eventually used on crops, is because of contaminated well water.  A lot of 
these wells are drilled in areas where natural arsenic deposits have leached into the water 
(Ambrosio et al., 2014). Two areas that have a true epidemic of arsenic poisoning in its 
groundwater and wells is Bangladesh and West Bengal (Kirchner and Weil, 1998).  In 
Bangladesh, a country of 125 million, the estimate of people exposed to toxic levels of 
arsenic range from 35 to 77 million people (Smith et al., 2000).  There, the Ganges delta 
aquifer that is used by the public for water is contaminated with arsenic (Acharyya et al., 
1999; Kirchner and Weil, 1998). Many of the wells were originally drilled in conjunction 
with UNICEF to try and provide these areas with water, and to prevent water-borne 
diseases like cholera and typhus (Alvarez, 2001). The WHO recommends a maximum 
concentration of arsenic in drinking water of 10µg/L. However, 35% of the wells in 
Bangladesh have concentrations above 50µg/L, and 8.4% of the wells have 
concentrations above 300µg/L (Smith et al., 2000). When levels exceed these thresholds, 
negative physical symptoms can arise.  
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Adverse Health Effects 
Undesired health effects from arsenic exposure include fever, diarrhea, and skin 
rashes (Dakeishi et al, 2006). In one study, researchers examined infants that were 
exposed to Morinaga dried milk in Japan that was accidently contaminated with arsenic.  
The 381 infants examined had clinical symptoms ranging from fever, diarrhea, vomiting, 
cough, eye discharge, skin pigmentation and rash, edema, and abdominal distension 
(Dakeishi et al., 2006).  
Many diseases and conditions can develop later in life due to chronic arsenic 
exposure. These include cardiovascular disease, diabetes, hearing loss, and anemia 
(Chappell et al., 1997). Some exposed people also develop Blackfoot disease, which is a 
disease of the blood vessels that can lead to gangrene, and eventual amputation of the 
foot (Tseng et al., 2005). More serious diseases like skin, bladder, and lung cancer 
develop as well due to arsenic exposure (Tchounwou et al., 2003).  
Although arsenic has been linked to causing cancer in adulthood, it has been used 
to cure cancer. In China, researchers used arsenic trioxide in conjunction with 
chemotherapy in patients with acute promyelocytic leukemia (APL). This resulted in 
remission rates ranging from 70-90% in newly diagnosed cases, and 65-90% in patients 
who had previously relapsed (Sun et al., 1992). In a follow up study of 32 patients, 16 of 
them survived more than 5 years with some living more than 17 years after the initial 
treatment (Sun et al., 1992). Similar results were seen in the United States when twelve 
APL patients were treated with 0.06-0.2 mg/kg/body weight of arsenic trioxide. The 
patients were treated until the leukemic blasts and promyelocytes were eradicated from 
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the bone marrow (Soignet et al., 1998). Of the 12 patients treated, 11 of them went into 
remission, and the only adverse side effects seen were rashes, slight fatigue, and 
musculoskeletal pain. More recently, arsenic trioxide was used in conjunction with 
dichloroacetate to induce cell death in breast cancer cells (Sun et al., 2011). Arsenic 
trioxide was seen to inhibit complex IV of the electron transport chain leading to a 
decrease in ATP production, and apoptosis of the cells (Sun et al., 2011). 
Developmental Health Effects of Arsenic 
 Arsenic can cause many undesired developmental outcomes as well. Many 
epidemiological studies have shown that in utero exposure can lead to miscarriages, 
infantile death, decreased weight gain, cardiovascular diseases, muscular issues and 
neurological issues (Concha et al., 1998; Raqib et al., 2009). Since arsenic easily crosses 
the placental barrier, and can come in contact with the embryo (Jin et al., 2006, Concha et 
al., 1998) this may explain some of these developmental effects on the newborn. 
One town that has become a natural experiment regarding chronic arsenic 
exposure is Antofagasta, Chile. The city and its 130,000 residents have exceedingly high 
levels of arsenic in their water supply. In the 60’s the arsenic was estimated to be around 
800 ppb in some wells and many dermatological and cardiovascular issues were being 
seen in the children (Borgono et al., 1977).  During this time, one study found that over 
70% of the children (n=37, 13-14 years) who grew up drinking the contaminated water 
had cutaneous lesions (Borgono et al., 1977). However, more serious developmental 
health effects have been seen. In one study, the authors examined over 400,000 residents 
in Northern Chile. They found that the mortality for bladder cancer among men in this 
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region was six times than that of the rest of Chile (Smith et al., 1998). In addition, lung 
cancer, skin cancer, and kidney cancer mortality was all significantly increased (Smith et 
al., 1998) 
 In West Bengal, India researchers studied over 200 women’s pregnancies. 
Amount of arsenic exposure was measured throughout the pregnancies and it was found 
that some wells had more than 200 µg/L of arsenic (Ehrenstein et al., 2005). Women who 
were exposed to these wells during their pregnancy then had a 6-fold increase of 
stillbirths (Ehrenstein et al., 2005). Even if the child is born to a mother who has been 
exposed to these high levels of arsenic, they often times have very low birth weights. 
Birth weight is a known to be very good indicator of a newborn’s overall health and 
physical and psychological development (Biswas et al., 2006). In one area in West 
Bengal, an epidemiological study looked at birth weight in newborns and found 31% of 
the newborns had low birth weight (< 2.5 kg, n=487) in the Puruliya region (Biswas et 
al., 2006). These newborns with low birth weight then have a much higher chance of 
dying, with 80 percent of neonatal deaths and 50 percent of infant deaths occur in 
conjunction with a low birth weight (Paul et al., 2002). Even in areas where arsenic 
exposure is not nearly as high (<50µg/L), the children born there are about 60g lighter 
than a child not exposed to arsenic (Hopenhayn et al., 2003). These results have been 
replicated in animal studies as well. When mice were exposed in utero to 10µg/L of 
arsenic, the arsenic cohort had low birth weights, weighing significantly less than the 
mice that were born to mothers not exposed to arsenic (Kozul-Horvath et al., 2012). 
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 In adolescence, other issues from arsenic exposure are often seen including many 
neurological deficits and lower intelligence quotients (IQ).  For example, in a follow-up 
study on the infants in Japan who had been exposed to arsenic-contaminated powered 
milk found that even fourteen years later, the poisoned individuals had higher incidences 
of abnormal electroencephalograms and lower intelligence quotients when compared to 
the control group (Dakeishi et al., 2006). In Bangladesh, children who have been 
chronically exposed to arsenic levels of 50µg/L or greater had significantly lower IQ’s, 
scoring up to 10 points lower than children who grew up drinking water that contained 
less than 5µg/L of arsenic (Wasserman et al., 2004). Another study done in South 
Carolina found increased mental retardation and developmental disability in children 
whose mothers were pregnant while living on land that had higher than average levels on 
arsenic in the soil (Liu et al., 2010). Of the 6048 mother child pairs, 1490 cases (24%) of 
mental retardation or developmental disability were seen (Liu et al., 2010). These 
neurological issues may be explained by arsenic’s ability to accumulate in the brain 
(Koehler et al., 2014; Xi et al., 2010). One study exposed astrocytes, a glial cell found in 
the brain and spinal cord that help form the blood-brain barrier and repair the brain and 
spinal cord following an injury, to arsenite and arsenate. After just 8 hours of exposure to 
1mM of arsenite, the astrocytes already had altered cell morphology and increase in 
lactate dehydrogenase, which is released in response to tissue damage (Koehler et al., 
2014). In addition arsenite was found inside the viable astrocytes after arsenite and 
arsenate exposure (Koehler et al., 2014). 
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In addition to these neurological deficits and lower IQ’s, sensorimotor deficits, 
impaired gaits, and muscle weakness is seen as well. One study found that 35-85% of 
people in regions like West Bengal and parts of Bangladesh where arsenic contamination 
is rampant have some sort of neuropathy and muscle weakness (Chakraborti et al., 2003). 
After an electromyographic test they found around 10% of the people chronically 
exposed to high levels of arsenic developed sensorimotor deficits and had impaired gait 
(Chakraborti et al., 2003; Mukherjee et al., 2003).  
P19 Cells 
The mouse P19 cell line is derived from a teratocarcinoma in mice and provides a 
good model to examine arsenic’s effects on cell lineage formation. They are pluripotent 
stem cells that can be induced to differentiate into any of the three germ layers, and show 
similar signaling pathways seen during early mouse embryogenesis (Kultima et al. 2010; 
Marikawa et al., 2009; McBurney, 1993). One of these crucial developmental pathways is 
the Wnt/ β-catenin pathway. This pathway is involved in the regulation of neural crest 
development and somitogenesis (Clevers et al., 2012; Schmidt et al., 2008). When mouse 
embryonic stem cells are deficient in β-catenin they exhibit self-renewal (Lyashenko et 
al., 2009); however, when β-catenin is overexpressed the stem cells will differentiate into 
muscle and neuronal cell lineages (Otero et al., 2004). We can use these muscle and 
neuronal lineages to examine arsenic’s effect on early embryogenesis. 
Our earlier studies have shown when P19 cells are induced to form embryoid 
bodies (EBs) while being exposed to 0.1µM, 0.5µM, and 1.0µM sodium arsenite, 
neurogenesis and myogenesis was suppressed (Hong and Bain, 2012).  The delayed 
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development in the cells exposed to arsenic was shown to be due the repression of many 
transcription factors (TFs), including Pax3, MyoD, myogenin, and NeuroD (Hong and 
Bain, 2012). The reduced expression of these TFs was thought to be due the repression of 
the Wnt/β-catenin pathway during early embryogenesis, due to reduced β-catenin 
expression (Hong and Bain, 2012).  Additional in vitro studies using different cells lines 
have shown similar degeneration to neuronal and muscle cells due to arsenic exposure. 
Reduced myelination of axons was seen when rats had 10mg of arsenite added to their 
drinking water daily (Garcia-Chavez et al., 2007), and when Neuro-2a cells were exposed 
to arsenic trioxide, neurite outgrowth was inhibited (Wang et al., 2010). Also, exposure 
of 1-2ppm of arsenic trioxide in mice’s drinking water resulted in degeneration of their 
neuronal cells in the cerebellum and cerebrum (Piao et al., 2005). 
Neural Plate Border Specifiers  
With these findings, it is of interest to identify the target cell population of 
arsenic. One potential target is the progenitor cells of the neural crest (NC). The NC is a 
migratory cell population that is unique to vertebrates and will form the peripheral 
nervous system and glia, many elements of the craniofacial skeleton, and muscle 
progenitors (Hong and Saint-Jeannet, 2007; Le Douarin and Kalcheim, 1999). Just after 
gastrulation, the ectoderm has three distinct regions including the non-neural ectoderm, 
neural plate, and the neural plate border (NPB) which is found in the middle (Hong and 
Saint-Jeannet, 2007; Milet and Mosoro-Burq, 2012). Numerous signals, including the 
Wnt signaling pathway (Garnett et al., 2012), are then sent into the NPB which induces 
the presumptive NC cells to become competent to the neural crest specifier signals 
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(Betancur et al., 2010). These cells will then undergo an epithelial to mesenchyme 
transition (EMT), delaminate, and migrate away from the neural tube (Trainor, 2005). 
The signals that induce the NC come from genes that are collectively known as the neural 
plate border specifiers (NPBS) (Betancur et al., 2010). These genes include many muscle 
cell lineage TFs Msx1, MyoD, and Myogenin, which are required for myogenesis, and 
neuronal cell lineage TFs Pax3, Sox10, and NeuroD1, which are required for 
neurogenesis during early embryonic development. Not much is known about the 
temporal-spatial aspects of these signals (Garnett et al., 2012). However, it is well known 
from previous studies that arsenic disrupts EB formation (Stummann et al., 2008), 
myogenesis (Garcia-Chavez et al., 2007), and neurogenesis (Piao et al., 2005; Wang et 
al., 2010) in mouse embryonic stem cells. 
Methylated Metabolites 
 
 In addition to inorganic arsenic, organic arsenic compounds are of major concern 
as well. Arsenic can be found in four oxidation states, +V, +III, 0, and –III, with 
pentavalent arsenate (As
V
) and trivalent arsenite (As
III
) being the most common species 
found (Sharma and Sohn, 2009). Once ingested, 80-90% of the arsenic is absorbed in the 
gastrointestinal tract (Freeman et al., 1995; Pomroy et al., 1980) and arsenic’s 
biotransformation processes create much more toxic methylated compounds.  First, 
inorganic arsenic is reduced between pentavalent and trivalent forms (Vahter, 2002) and 
a methyl group is added from S-adenosylmethionine (SAM) through a SAM-dependent 
As
III
 methyltransferase (Lin et al., 2002). This leads to the production of the methylated 
metabolites monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) (Vahter, 
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2002; Styblo et al., 2002) which are the primary metabolites excreted in urine (Styblo et 
al., 2002).  
The most toxic methylated species produced are monomethylarsonous acid 
(MMA III) and dimethylarsinous acid (DMA III) and have been found to increase in 
concentration during pregnancy (Gardner et al., 2011) which can exert toxic effects on 
the developing fetus. Epidemiological studies have shown that pregnant women in 
chronically exposed areas like Bangladesh have increased concentrations of arsenic in 
their urine. In Matlab, Bangladesh urinary arsenic levels were as high as 84µg/L at 30 
weeks gestation (Tofail et al., 2009). Similar results were found in Chilean women whose 
urinary arsenic levels increased from 36µg/L at 20 weeks gestation, to 47µg/L at 36 
weeks gestation (Hopenhayn et al., 2003). 
In vitro studies have examined the effects of these methylated metabolites on 
cells. Cultured human and rat hepatocytes were exposed to As
III
 and As
V
 and methylated 
species as well at concentrations ranging from 0.4-20µM (Styblo et al., 2000). The 
pentavalent species were not found to be cytotoxic; however, the trivalent species 
significantly decreased cell viability in a concentration dependent manner (Styblo et al., 
2000). Another study found the even levels of MMA (III) as low as 1µM stopped the 
differentiation of mouse embryonic stem cells into cardiomyocytes (Wang et al., 2014).  
Thesis Goals and Objectives 
 
The goal of this thesis was to determine if arsenic affects the number and/or 
location of the neural plate border specifier cells. With previous studies showing arsenic 
reduces neuronal and skeletal differentiation during early embryogenesis through the 
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Wnt/β-catenin signaling pathway, we were interested in determining the target cell 
population of arsenic. We hypothesized that arsenic was targeting the neural plate border 
specifier cells, and its downstream targets, by reducing the signals required for 
neurogenesis and myogenesis. An additional area of research of this study is to examine 
if a mono-methylated or di-methylated species of arsenic is more or less toxic to the cells. 
My goals for this thesis were two-fold: 
1) To determine if arsenic affects the number and/or location of neural plate 
border specifier cells. Pluripotent P19 cells will be cultured and induced to from 
embryoid bodies. The embryoid bodies will be exposed to sodium arsenite and 
immunohistochemistry will be used to determine expression levels of the transcription 
factors involved.  
2) Examine the level of developmental toxicity of a mono-methylated and di-
methylated species of arsenic. The same methods described from above will be used, but 
the embryoid bodies will be cultured with a mono-methylated and di-methylated species 
of arsenic. 
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Abstract  
Epidemiological studies have shown correlation between arsenic exposure and 
adverse developmental outcomes. Exposure to arsenic and its metabolites during early 
embryogenesis can cause reduced weight gain and neurological deficits later on in life. 
Additionally, in vitro and in vivo studies have shown that arsenic suppresses neurogenesis 
and myogenesis through Wnt/β-catenin signaling pathway by stopping the differentiation 
of precursor cells. This study used P19 mouse embryonic stem cells to determine the 
target cell population of arsenic its metabolites. Pluripotent P19 cells were exposed to 
0.1μM and 0.5μM sodium arsenite, 0.01μM and 0.05μM MMA III, and 0.001μM and 
0.005μM DMA III. On day 2, in the neurogenic pathway, and day 3 in the myogenic 
pathway, arsenic is targeting the differentiation of neural plate border specifier (NPBS) 
cells, which resulted in a 1.2-fold reduction of Pax3 and a 1.5-fold reduction in Msx1 
protein. Arsenic also altered the nuclear localization of Msx1 on day 2 by 1.5-fold, 
resulting in reductions in both MyoD nuclear expression on days 2-5, and in NeuroD1 
nuclear expression on days 4-5.  Arsenic exposure also altered co-localization patterns in 
both the neurogenic and myogenic lineages.  
After exposure to arsenic’s metabolites, MMA III and DMA III, MMA III was 
seen to target the neural plate border specifier cells on day 3 in both the neurogenic and 
myogenic pathways, while DMA III does not affect transcription factor expression until 
day 5. MyoD’s nuclear localization was significantly decreased on day 3 and 5 in both 
the MMA and DMA treatments. In the neurogenic pathway, NeuroD1’s nuclear 
localization was significantly decreased by1.4-fold in day 5 EBs after exposure to both 
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MMA and DMA. In conclusion, these results suggest that arsenic and its metabolites are 
targeting the precursor cells to skeletal muscles and sensory neurons, and are therefore 
suppressing neurogenesis and myogenesis. 
 
Key Words: arsenite, dimethylarsinous acid, P19 cells, monomethylarsonous 
acid, myogenesis, neurogenesis 
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Introduction 
 
Arsenic is a known toxicant that poses many threats to human health. It is a 
naturally occurring element found in bedrock, and its weathering has resulted in arsenic 
contamination of groundwater in many parts of the world (Kirchner and Weil, 1998; 
Yang et al., 2009). In the West Bengal region of India, it is estimated that more than 26 
million individuals have been exposed to drinking water contaminated with arsenic (As) 
(Mondal et al., 2010).  Although the World Health Organization recommends a 
maximum concentration of arsenic in drinking water of 10 µg/L, some wells in West 
Bengal have up to 531 µg/L As (Desbarats et al., 2014). Arsenic has also been found as a 
contaminant in food, such as rice, with levels ranging from 0.15-0.36 mg/kg (Zavala and 
Duxbury, 2008).  For an average adult consuming 400 g of rice per day containing 0.25 
mg/kg, their intake is approximately 100 µg As, which is equivalent to five times the 
amount of arsenic an adult would get from drinking 2L of water at the 10 µg/L limit 
(Zavala et al., 2008). In particular, increased arsenic levels in the urine of pregnant 
women and children have been seen due to the consumption of rice products (Davis et al., 
2012). 
Once inside the body, arsenic can be methylated by arsenic methyltransferases in 
a series of metabolism steps, with monomethylarsonous acid (MMA) and 
dimethylarsinous acid (DMA) being the primary species excreted in the urine (Styblo et 
al., 2002).  It is known that the concentrations of MMA and DMA increase during 
pregnancy (Concha et al., 1998; Hopenhayn et al., 2003; Gardner et al., 2011). For 
example, a study of Chilean pregnant women whose drinking water contained at least 40 
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μg/L determined that at ~20 weeks of gestation, average urinary arsenic levels were 36 
μg/L, while at ~36 weeks of gestation, urinary arsenic levels had increased to 54 μg/L 
(Hopenhayn et al., 2003). Furthermore, DMA levels increased from 30 μg/L to 47 μg/L.  
In vitro studies have shown that some arsenic metabolites, especially the trivalent 
species, are more toxic than arsenic itself. For example, MMA (III) at concentrations 
between 0.5-1 μM inhibited the differentiation of mouse ES-D3 stem cells into 
cardiomyocytes more strongly than arsenic trioxide or DMA (III) (Wang et al., 2014). In 
another study, MMA (III) caused a decrease in myeloid progenitor colonies at 
concentrations as low as 0.13μM (Ferrario et al., 2008). Since there is an increase in 
arsenic biotransformation and methylated metabolites during pregnancy, continuous 
exposure to these metabolites could also have adverse effects on the developing fetus. 
Epidemiological studies have shown that in utero exposure to arsenic can lead to 
increased occurrence of neonatal death, low birth weight, and miscarriages (Concha et al., 
1998; Raqib et al., 2009).  It has been show that during pregnancy, exposure to even 
moderate levels of arsenic in drinking water (<50 µg/L) can result in a 57g reduction in 
birth weight (Hopenhayn et al., 2003), and levels 67-85 µg/L are correlated with a 3-fold 
increase in miscarriages (Ogata et al., 2014). Mice exposed to 10µg/L As in utero and 
during the postnatal period weighed significantly less than control mice (Kozul-Horvath 
et al., 2012). These outcomes are thought to result from arsenic’s ability to cross the 
placental barrier, and come in contact with the embryo (Jin et al., 2006, Concha et al., 
1998).  For example, cord blood and placenta contained an average of 9 and 34 µg/L 
arsenic, respectively, in women drinking water containing 200 µg/L of arsenic, compared 
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to a placental concentration of 7µg/kg in women who were not exposed to arsenic 
(Concha et al., 1998). 
Embryonic arsenic exposure has also been correlated with many neurological 
deficits, such as decreased pattern memory (Tsai et al., 2002) and mental retardation in 
adolescents (Dakeishi et al., 2006, Liu et al., 2010).  A follow-up study fourteen years 
after infants were exposed to As-contaminated dry milk found that the adolescents had 
lower intelligence quotients when compared to the control group (Dakeishi et al., 2006). 
Similar results were found in children from Bangladesh.  When their drinking water 
contained >50 μg/L arsenic, they scored significantly worse on IQ tests than children who 
drank water from wells with <5 μg/L (Wasserman et al., 2004) Since arsenic has the 
ability to accumulate in the brain, which has been shown in rats (Xi et al., 2010), this may 
explain the connection between increased embryonic exposure to arsenic and 
neurological deficits.   Collectively, these studies suggest that arsenic impacts the 
development of neurons and skeletal muscle.   
In vitro studies have also shown similar impacts of arsenic on cellular 
development and differentiation.  For example, when Neuro-2a cells were exposed to 
3μM arsenic trioxide, neurite outgrowth was inhibited (Wang et al., 2010).  Our lab has 
previously showed that neurogenesis and myogenesis was suppressed when P19 mouse 
stem cells were exposed to 0.5µM arsenite, due to reductions  of many developmentally-
important transcription factors (TFs), such as Pax3, MyoD, Myogenin, and NeuroD 
(Hong and Bain, 2012). Since arsenic appears to impact skeletal muscle and neurons 
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during embryogenesis, there is likely a common progenitor cell type that is a target of 
arsenic.  
One potential target cell type is the progenitors of the neural crest (NC), termed 
neural plate border specifier (NPBS) cells. These cells send out signals into the neural 
plate border (NPB) region to induce neural crest (NC) formation and also delineate the 
location of the somites (Sauka-Spengler and Bronner-Fraser, 2008.) Numerous signals, 
including the Wnt signaling pathway (Garnett et al., 2012), are then sent into the NPB 
region, which induces the presumptive NC cells to become competent to the neural crest 
specifier signals (Betancur et al., 2010). These cells will then undergo an epithelial to 
mesenchyme transition (EMT), delaminate, and migrate away from the neural tube 
(Trainor, 2005). The signals that induce the NC come from genes that are collectively 
known as the neural plate border specifiers (NPBS) (Betancur et al., 2010). The signals 
produced include many transcription factors that are required for neurogenesis, such as 
Pax3, Sox10, and NeuroD (Howard, 2005), and required for myogenesis, such as Msx1, 
MyoD, and Myogenin (Yokoyama and Asahara, 2011). 
The objective of this study was to determine whether arsenic specifically targets 
the neural plate border specifier cells during embryogenesis, thereby impairing 
appropriate differentiation into sensory neurons and skeletal muscle cells.  Further, we 
wanted to examine whether the metabolites of arsenic differed in their ability to reduce 
cell differentiation.  Our results suggest that early exposure to arsenite and its methylated 
metabolites target the differentiation of neural plate border specifier cells by reducing the 
expression of Pax3, Sox10, and NeuroD1 in the neurogenic pathway, and Msx1 in the 
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myogenic pathway. 
 
Materials and Methods 
P19 cell culture and differentiation of embryoid bodies 
The mouse P19 mouse embryonal carcinoma cell line (ATCC, Manassas, VA) 
was maintained in α-MEM containing 7.5% bovine calf serum (Hyclone, Logan, UT), 
2.5% fetal bovine serum (Mediatech, Manassas, VA), 1% L-glutamine, and 1% 
penicillin/streptomycin (designated as growth medium) at 37°C in a humidified incubator 
containing 5% CO2. The medium was changed every 48 hours.  
To form embryoid bodies and induce differentiation, P19 cells were aggregated 
using the hanging drop method (Wang and Yang, 2008). Briefly, P19 cells were 
trypsinized and suspended in differentiation medium (growth medium with 1% dimethyl 
sulfoxide) with 0, 0.1, and 0.5 µM sodium arsenite at a density of 500 cells/20 µl drop. 
These concentrations correspond to 7.5 and 37.5 µg/L arsenic.  Each replicate contained 
96 drops (n=3 replicates per concentration and per day).  The hanging drops were 
allowed to form into embryoid bodies (EBs) for 2 days, after which, each drop was 
transferred to a 96-well ultralow attachment plate containing 70 µl of fresh differentiation 
medium with 0, 0.1, or 0.5µM arsenite. The EBs were collected at days 2, 3, 4, and 5, 
fixed in 10% neutral buffered formalin (NBF) overnight at 4
o
C, dehydrated in ethanol, 
cleared in xylene, embedded in paraffin, and then sectioned for use in 
immunohistochemistry. 
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Synthesis of monomethylarsonous acid (As
III
(CH3)(OH)2, MMA(III)) 
 
 Synthesis of the MMA(III) precursor [As(CH3)O]n was performed as reported 
(Cullen et al., 1989) with minor modifications.  Arsenic trioxide (20 g, 101.1 mmol) was 
dissolved in aqueous sodium hydroxide solution (100 mL, 0.01 M) before adding methyl 
iodide (126 mL) and heating to reflux for 24 h. After cooling, ethanol (100 mL) was 
added to precipitate a white solid that was then filtered and dried, yielding disodium 
methylarsonate (16.48 g). Disodium methylarsonate was then dissolved in warm water 
(60 mL), and sulfur dioxide (generated in situ
4
 as described below) was bubbled through 
the solution for 15-20 min. The resulting solution was heated to boiling for 2 min, cooled 
to 0 
o
C, and neutralized with sodium carbonate until bubbling ceased. The neutralized 
solution was evaporated to dryness and was extracted with benzene (other similar 
solvents such as toluene did not work for this extraction). Benzene was removed in vacuo 
to yield [As(CH3)O]n as a white solid (7.5 g, 69.5% yield). The 
1
H NMR (CDCl3) 
spectrum was consistent with reported values (Cullen et al., 1989), and the MALDI mass 
spectrum showed a single peak at 106.8 m/z for [As(CH3)O + H
+
].  The desired 
MMA(III) product was formed by dissolving [As(CH3)O]n in water (Cullen et al., 1989; 
Mass et al., 2001). 
 
Synthesis of dimethylarsonous acid (As
III
(CH3)2OH, DMA(III)) 
Synthesis of this compound was performed as reported (Burrows and Turner, 
1920) with minor modifications.  Cacodylic acid (12.5 g, 90.5 mmol) and potassium 
iodide (40 g, 240.9 mmol) were dissolved in water (50 mL), and sulfur dioxide 
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(generated in situ) (Descriptive Inorganic Chemistry, 2006) was bubbled through the 
solution for 10 min. A 1:1 solution of concentrated hydrochloric acid and water (25 mL) 
was then added periodically to the reaction mixture over the course of 30 min until a 
yellow oil formed and elemental sulfur precipitated. The oil layer was separated, dried 
over CaCl2, and distilled to afford dimethylarsonous acid (16.8 g, 80% yield). The 
melting point of the purified compound was -35 ˚C, consistent with the reported value 
(Burrows and Turner, 1920). The 
1
H NMR spectrum of DMA(III) in CDCl3 showed a 
single resonance at  1.97, and the MALDI mass spectrum showed a single peak at 123 
m/z for [As
III
(CH3)2OH + H
+
]. 
 
In situ synthesis of SO2  
Sodium metabisulfite (Na2S2O5,10 g) was added to a two-neck, round-bottomed 
flask (250 mL) and concentrated sulfuric acid (100 mL) was added dropwise periodically 
as effervescence ceased. From this flask, a vacuum adaptor attached to tubing with a 
glass pipette at the end was used to bubble SO2 through the reaction solutions as 
described (Descriptive Inorganic Chemistry, 2006). 
 
Embryoid body exposure to MMA and DMA  
To derive appropriate monomethylarsonous acid (MMA) and dimethylarsinous 
acid (DMA) concentrations, dose-response experiments were carried out using varying 
MMA (0-0.1µM) and DMA (0-0.01µM) concentrations.  The P19 cells were aggregated 
into embryoid bodies as described above and allowed to differentiate for 12 days, 
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changing the medium every 48 hours.  Cells were examined visually under the 
microscope for viability and differentiation (data not shown).  Concentrations of 0.01 and 
0.05µM MMA, and 0.001 and 0.005µM DMA were chosen as appropriate levels that 
inhibited differentiation at the highest concentration without causing overt cellular death.  
P19 cells were cultured and differentiated as described above. On days 3 and 5, the EBs 
were collected, fixed in 10% NBF, and then used for immunohistochemical analysis as 
described above. 
 
Immunohistochemistry 
The fixed and embedded EBs were cut in 5 µm sections, placed on slides, 
deparaffinized, and rehydrated in graded ethanol washes.  Antigen retrieval was carried 
out with citric acid buffer (pH=6) and then microwaved. The slides were blocked (1X 
PBS, 5%BSA, 0.05% Tween-20) for 1 hr.  Primary antibodies were incubated at a 1:200 
dilution overnight at 4
o
C, and included Pax3 (Gene Tex no. GTX100663), Sox 10 
(Abnova no. H00006663-M01), NeuroD1 (Abcam no. AB60704), Msx1 (Sigma-Aldrich 
no. SAB2500650), MyoD (Santa Cruz no. SC304), and Myogenin (Imgenex no 
IMG131).   The secondary antibodies (1 µg/ml) conjugated to Alexa Fluor 488 (anti-
goat), Alexa Fluor 488 (anti-mouse), Alexa Fluor 594 (anti-rabbit) or Alexa Flour 647 
(anti-mouse) (Invitrogen) were incubated with the slides, which were counterstained with 
DAPI (Invitrogen).  Alexa Fluor 488 (anti-goat), Alexa Fluor 594 (anti-rabbit) and Alexa 
Fluor 647 (anti-mouse) were multiplexed together for Msx1, MyoD and Myogenin 
staining. Alexa Fluor 594 (anti-rabbit) and Alexa Fluor 647 (anti-mouse) were 
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multiplexed together for Pax3 and NeuroD1 staining. Alexa Fluor 488 (anti-mouse) was 
used for Sox10 staining. Slides were examined by conventional immunofluorescence on a 
Nikon Ti Eclipse Inverted Microscope. 
 
Analysis of protein expression 
To determine the overall expression of each transcription factor, its intensity was 
calculated using ImageJ following the protocol developed Arques et al., 2012.  Briefly, a 
region of interest (ROI) was defined around each embryoid body in the blue (DAPI) 
channel and an integrated density value (IDV) calculated. This was then repeated for each 
channel of interest. Next, ten representative nuclei covering different sizes and intensities 
throughout the blue channel ROI were marked using the elliptical selection tool, and an 
average IDV was calculated.  Next, the blue channel IDV was divided by the mean 
nucleus value, resulting in the average number of cells present in each ROI. Then, to 
calculate individual protein content per EB, each respective channel IDV (green, red, far 
red) was divided by the average number of cells. 
To examine nuclear localization of specific transcription factors, and co-
localization of multiple transcription factors, a 50 µm x 100 µm grid was overlaid in the 
bottom right-hand corner of each image.  Approximately 100 cells were counted per 
image and scored as to whether each transcription factor was localized in the nucleus of 
the cell, and whether two or more transcription factors were co-localized together. 
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Statistical analysis 
For image intensity, the replicates (n=3) of each treatment, day, and transcription 
factor were averaged together and statistical significance determined by ANOVA 
followed by Tukey’s (p<0.05).  Nuclear localization and co-localization numbers were 
converted into percentages for each treatment, day, and transcription factor(s) (n=3) and 
statistical significance determined by ANOVA followed by Tukey’s (p<0.05).   
 
Results 
Time course of transcription factor expression and nuclear translocation in P19 cell-
derived embryoid bodies 
 
To determine if arsenic or its metabolites targeted the neural plate border specifier 
(NPBS) cells and impacted their differentiation, a time-course of transcription factor 
expression during embryoid body formation was first determined.  Key protein markers 
of NPBS cells include Msx1 and Pax3 (Sauka-Spengler and Bronner-Fraser, 2008; 
Betancur et al., 2010).  Along the neurogenic lineage, NPBS cells differentiate into neural 
crest (NC) progenitor cells by expressing the transcription factor Sox10 (Sauka-Spengler 
and Bronner-Fraser, 2008). The NC progenitor cells then differentiate into NC cells, 
expressing the transcription factor NeuroD1 before developing into sensory neurons 
(Betancur et al., 2010). Along the myogenic lineage, NPBS cells differentiate into 
myogenic progenitor cells, expressing the transcription factor MyoD (Miner and Wold; 
1991; Ridgeway et al., 2000). The myogenic progenitor cells then differentiate into 
myocytes, expressing Myogenin, and then finally develop into Myotubes (Ridgeway et 
  
 31 
al., 2000). To determine the temporal aspects of each transcription factor, its expression 
was examined in day 2, 3, 4, and 5 embryoid bodies (EBs). 
In the neurogenic lineage, Pax3, a marker of neural plate border specifier (NPBS) 
cells, and Sox10, a marker of neural crest progenitors, had steady, medium expression 
throughout days 2-5 (Table 1).  NeuroD1, a neural crest cell marker, is not expressed on 
days 2-3, but has high expression on day 4, and medium expression on day 5 (Table 1). 
In the myogenic lineage Msx1, a NPBS cell marker had low expression on day 2, 
high expression days 3-4, and medium expression on day 5 (Table 1). MyoD, a myogenic 
progenitor marker, expression has medium expression throughout days 2-5 (Table 1). 
Myogenin, which is a marker for myocytes, is not expressed on days 2-4, and has low 
expression on day 5 (Table 1). 
When looking at the percent nuclear localization, on day 2 only Pax3 has at least 
50% nuclear localization (Table 1; Figure 1C).  Sox10, Msx1, and MyoD are mainly 
found in the cytoplasm with 1-10% nuclear localization on day 2 (Table 1; Figure 1C). 
Sox10 and Msx1 stay this way throughout days 2-5 (Figure 1C-4C), while MyoD’s 
translocation to the nucleus increases on days 3-5 (Table 1; Figure 2C-4C).  NeuroD1 is 
not expressed until day 4, but once expressed, it is predominantly expressed in the 
nucleus on days 4 and 5 (Table 1; Figure 3 and 4C). Myogenin, which is not expressed 
until day 5, is predominantly found in the cytoplasm (Table 1; Figure 4C). 
 
Arsenic targets neural plate border specifier cells  
 
To determine whether neural plate border specific cells are the target cell 
population of arsenic, embryoid bodies (EBs) were exposed to 0, 0.1, and 0.5µM sodium 
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arsenite and expression of transcription factors along the muscle and neural lineages 
examined.  After 2 days of exposure, the 0.1 and 0.5µM treated cells showed a significant 
15-19% decrease in Pax3 intensity (Figure 1 A and B).  After 3 days of arsenic exposure, 
Sox10 expression was also significantly decreased by 30% and 51% in the 0.1 and 0.5 
µM treatments, respectively (Figure 2). After 4 and 5 days of arsenic exposure, NeuroD1 
expression was decreased by 23% in the 0.5 µM treatment (Figure 3A and B; Figure 4A 
and B).  In the neurogenic pathway, it appears that arsenic is targeting the neural plate 
border specifier cells starting on day 2, which results in reduced transcription factor 
expression indicative of both neural crest progenitor cells and neural crest cells (Table 2).  
Within the muscle lineage, only Msx1 expression was significantly decreased (34%) in 
the 0.5 µM treatment on day 3 (Figure 2 A and B).  No other transcription factor levels 
were altered on any of the remaining days due to arsenic exposure (Table 2).   
 
Monomethylarsonous acid (MMA III) and dimethylarsinous acid (DMA III) targets 
neural plate border specifier cells 
 
Since methylated arsenical metabolites often have higher toxicity than that of the 
inorganic species (Ferrario et al., 2008; Wang et al., 2014), P19 cells were exposed to 
MMA(III) and DMA(III) for either 3 or 5 days, and the expression of transcription 
factors along the muscle and neural lineages were examined.   After 3 days of exposure to 
MMA , Msx1, MyoD, Pax3 and Sox10 expression were significantly decreased in the 
0.05 µM treatment by 22%, 11%, 7%, and 26%, respectively (Figure S1; Figure 5 A). 
After 5 days of MMA exposure, only the neurogenic lineage was affected with Pax3, 
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Sox10 and NeuroD1 showing a significant reduction in expression of 10%, 11%, and 
13%, respectively in the 0.05 µM treatment  (Figure S2; Figure 6A). 
None of the transcription factor levels were reduced after 3 days of DMA 
exposure (Figure S3; Figure 7 A). However, after 5 days of DMA exposure, Msx1, 
MyoD and Myogenin were all significantly reduced by 17%, 12%, and 22%, respectively 
(Figure S4; Figure 8 A). In the neurogenic pathway, Sox10 and NeuroD1 showed a 
significant decrease in the 0.005 µM treatment by 13% and 9% (Figure S4; Figure 8 A). 
In the neurogenic pathway, it appears that MMA is targeting the neural plate 
border specifier cells on day 3 while DMA does not affect transcription factor expression 
until day 5 ( Table 4).  
 
Arsenic alters nuclear localization of transcription factors 
 
In addition to examining overall transcription factor expression, their cellular localization 
was also examined. In the myogenic pathway after 2 days of arsenic exposure, Msx1 
nuclear localization was significantly decreased by 1.5-fold, while MyoD nuclear 
expression was reduced by 3.4-fold in the 0.5µM treatment (Figure 1C).  On days 3, 4, 
and 5, MyoD nuclear localization continues to be reduced in the 0.5 µM treatment by 2.2, 
1.2-, and 1.2-fold, respectively (Figure 2-4C). On both days 4 and 5, NeuroD1 nuclear 
expression was significantly reduced in the 0.5 µM treatment by 1.1- and 1.4-fold, 
respectively (Figure 3-4C).  
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Monomethylarsonous acid (MMA III) and Dimethylarsinous acid (DMA III) alters 
nuclear localization of transcription factors 
 
After 3 days of exposure to MMA III (0.05 µM) and DMA III (0.005 µM), MyoD 
nuclear localization was significantly decreased by 2-fold and 1.5-fold (Figure 5B and 
7B; Table 5).  After 5 days of exposure to MMA III and DMA III, MyoD nuclear 
localization was again significantly decreased by 1.1-fold and 1.3-fold, at the highest 
concentrations (Figure 6B and 8B). In addition, NeuroD1 nuclear localization was 
significantly decreased in both the MMA III and DMA III treatments at the highest 
concentrations after 5 days of exposure by 1.4-fold (Figure 5C and 7C). 
 
Arsenic alters co-localization patterns  
In addition to looking at overall intensity and nuclear localization of the 
transcription factors, their co-localization patterns within the cells were examined as well. 
In the myogenic pathway, Msx1 and MyoD co-localized together predominately in the 
cytoplasm on days 2-4.  However, the frequency of them being together in the same cell 
drops from 98% on day 2, to 73% on day 3, and only 38% on day 4 (Figures 1-3).  When 
treated with arsenic, on day 2 of differentiation, the overall co-localization of these two 
transcription factors is decreased by 1.5-fold (Figure 1).  By differentiation day 4, arsenic 
exposure does not alter the overall percentage of cells co-expressing Msx1 and MyoD, 
however, arsenic does significantly increase the percentage of cells expressing these 
transcription factors exclusively in the cytoplasm from 34% to 42% (Figure 3).  
In the neurogenic pathway, Pax3 and NeuroD1 are expressed in the same cells 82-
84% of the time on days 4 and 5.  Their co-expression is predominately located in the 
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nuclei (Figure 3-4), although this drops from 77% on day 4 to 66% on day 5.  When cells 
are exposed to arsenic, there is a significant shift towards the co-expression being in the 
cytoplasm rather than in the nuclei, such that on day 5, co-localization of Pax3 and 
NeuroD in the nucleus drops from 66% of cell to 48% of cells.    
 
Monomethylarsonous acid (MMA III) and dimethylarsinous acid (DMA III) alters co-
localization patterns 
 
After exposure to MMA, similar co-localization patterns were seen in the 
myogenic pathway.  For example, the frequency of Msx1 and MyoD being expressed in 
the same cell on day 3 of differentiation decreases from 78% in the controls to 66% in the 
0.05 µM MMA group (Figure 5).  With DMA, while there is not an overall reduction in 
Msx1 and MyoD expression in the same cell, there is a shift in cellular localization 
patterns.  DMA exposure reduces the nuclear co-expression of Msx1 and MyoD by 3.6-
fold (Figure S3). Interestingly, neither MMA nor DMA alter the co-localization of Pax3 
and NeuroD on day 5 of differentiation (Figure S2 and S4). 
 
Discussion 
 
The results from this study show that arsenic and its methylated metabolites 
(MMA and DMA) inhibit neurogenesis and myogenesis in P19 cells by targeting the 
neural plate border specifier cells. In addition, arsenic and its metabolites were shown to 
alter nuclear localization, and co-localization patterns of the key markers involved in 
neurogenesis and myogenesis.  
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 Starting on day 2 of sodium arsenite exposure, it was already apparent that the 
neural plate border specifier (NPBS) cells were being targeted. In the neurogenic lineage, 
in both the 0.1 and 0.5 µM treated cells, a significant decrease in Pax3 intensity was seen. 
Similar findings have been found in our lab. After P19 cells were exposed to 0.1 and 0.5 
µM sodium arsenite Pax3 protein was reduced in day 2 EBs (Hong and Bain, 2012). It is 
known that during embryogenesis, Pax3, a marker of NPBS cells, is activated by the 
Wnt/β-catenin pathway (Marikawa et al., 2009). However, in order for neural crest 
specification to occur, Zic1 need to be activated at the same time as Pax3 (Betancur et al., 
2010). Pax3 alone is only capable of causing moderate induction of the neural crest 
program followed by migration and differentiation (Milet et al., 2013). Zic1 expression 
alone activates snail1, an early neural crest specifier (Plouhinec et al., 2014). Once 
activated, the Pax3/Zic1 combination activates a cascade of genes involved in neural 
plate border formation, including snail2, another neural crest specifier, and Sox10 
activation later on during neurulation (Milet et al., 2013). The co-activation of these TFs 
causes additional NPBS expression and the neural crest to begin its EMT, migration, and 
differentiation (Milet et al., 2012). The Pax3/Zic1 combination then helps regulate the 
differentiation of neurons and skeletal muscle by activating further transcription factors 
required for myogenesis and neurogenesis (Ridgeway et al., 2000). In addition to the 
Pax3/Zic1 co-activation, Pax3 has recently been found to target itself. It was found that 
there are Pax3 binding sites upstream of its promoter (Plouhinec et al., 2014), indicating 
that there is a positive feedback loop in addition to the Pax3/Zic1 co-expression that is 
driving the neural crest gene regulatory network. 
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The reduction in Pax3 expression may help explain the decrease in Sox10, a 
marker of neural crest progenitors, on day 3, and a reduction in NeuroD1, a neural crest 
cell marker, on days 4 and 5. As mentioned before, the Pax3/Zic1 co-expression, in 
addition to the positive feedback loop of Pax3 on itself, activates a cascade of genes 
involved in neurogenesis, including Sox10 (Milet et al., 2013). Studies have shown that 
Pax3 and Sox10 physically interact in complex signaling pathways and protein-protein 
interactions (Lang and Epstein, 2002). Once Pax3 is bound to the DNA, it interacts with 
Sox 10 via the Pax3 paired domain (PD) (Lang and Epstein, 2002) resulting in increased 
transcriptional activity. Normally, Sox10, a marker of neural crest progenitors, then 
activates Islet1 (Isl1) whose role is to carry out the terminal differentiation of neurons 
involving activation of basic helix-loop-helix genes such as NeuroD (Radde-Gallwitz et 
al., 2004). 
Normally, Sox10 expression begins when neural crest progenitors start to migrate 
from the neural tube and its expression starts to decrease as the cells differentiate into 
neural crest cells, which express NeuroD1 (Britsch et al., 2001). It makes sense that if 
there is a reduction on Pax3 on day 2, that there would be a reduction in subsequent 
transcription factors, including Sox10 and NeuroD1 leading to a reduction in 
neurogenesis. 
Regarding the muscle lineage, the NPBS cells were again being targeted. This 
was apparent due to the significant decrease in the expression of the NPBS cell marker 
Msx1 on day 3.  It is interesting to note that no other transcription factor levels were 
altered on any of the remaining days due to arsenic exposure (Table 2). One possible 
  
 38 
explanation is the protein-protein interaction between Msx1 and Pax3. Normally, Msx1 
expression overlaps the expression of Pax3, as shown in migrating limb muscle 
precursors (Bendall et al., 1999).  Pax3 expression is then downregulated once myogenic 
regulatory transcription factors are expressed (Kuang et al., 2006; Goulding et al., 1994; 
Williams and Ordahl, 1994), such as MyoD. These muscle precursors are committed to 
form myoblasts, which express markers such as MyoD. Pax3 then promotes the 
delamination and migration of these muscle precursors from the neural tube 
(Buckingham, 2007; Bajard et al., 2006).  In our study, there was a decrease in Msx1 
intensity on day 3 with no decrease of subsequent markers such as MyoD or Myogenin. 
This could due to the fact that since Msx1 expression has decreased, there is a decrease in 
the Msx1-Pax3 protein-protein interaction, and Pax3 is still able to activate MyoD 
expression, as seen in previous studies (Buckingham, 2007; Bendall et al., 1999). 
 With arsenic’s methylated metabolites; monomethylarsonous acid (MMA III) and 
dimethylarsinous acid (DMA III), some differences between the treatments were seen.  In 
the neurogenic pathway, there was an early decrease in Pax3 and Sox10 on day 3 after 
MMA exposure, but not after 3 days of DMA exposure.  It seems that MMA targets the 
NPBS cells early on, where DMA does not. There was then a subsequent decrease in 
expression of NeuroD1 on day 5 in both the MMA and DMA treatments, indicating that 
they were targeting the neural crest cells.  With the myogenic pathway’s response to 
MMA III and DMA III treatment, there was an early decrease in Msx1 and MyoD 
expression seen on day 3 in the MMA treatment, but not the DMA treatment, potentially 
indicating again that MMA is targeting the NPBS cells much earlier than DMA, and 
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possibly that the DMA concentrations were too low to cause an effect. There were then 
no subsequent decreases in any markers on day 5 in the MMA treatment, but all of the 
myogenic markers (Msx1, MyoD, Myogenin) were decreased in the DMA treatment on 
day 5. These findings, first, show that methylated metabolites are more toxic to the cells 
at a much lower concentration than sodium arsenite, which is consistent with other 
studies (Wang et al., 2014; Ferrario et al., 2008). The methylated metabolites have been 
shown to have a high binding affinity to thiol groups in proteins and are very good at 
inhibiting enzymes (Styblo etl., 1997)   It is also interesting to note that P19 appear to 
have arsenic methylation capabilities. Arsenite methyltransferase (As3MT) is the enzyme 
that transfers the methyl group from SAM turning arsenite into MMA (Albores et al., 
1992), and at least its transcript is present in stem cells both before and after 
differentiation into embryoid bodies (Supplementary Figure 5). Second, these results 
suggest that the neural lineage seems to be affected much more than the myogenic 
lineage after exposure to MMA III and DMA III.  This is also confirmed when looking at 
the sodium arsenite exposures.  
Finally, nuclear localization and co-localization of the markers, NeuroD1 and 
MyoD are altered during the differentiation process in exposure to sodium arsenite (Table 
3), MMA III and DMA III (Table 5). It appears that arsenic and its metabolites are 
inhibiting the translocation of the markers to the nucleus. Arsenic itself could be targeting 
the transcriptional complex of these markers.  Normally, all of the basic helix-loop-helix 
proteins (bHLH) bind to a consensus E-box sequence (CANNTG) (Berkes and Tapscott, 
2005).  MyoD forms a heterodimer with E-protein, a sub-family of bHLH proteins, by 
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interacting with the HLH domains (Lassar et al., 1991; Murre et al., 1989) which mediate 
additional bHLH dimerization (Berkes and Tapscott, 2005).  MyoD then activates further 
gene transcription by binding to E-boxes in the promoter region of the skeletal muscle 
genes (Tapscott, 2005). Many of these binding sites recognize sub-families of the bHLH 
proteins like NeuroD (Tapscott, 2005). Arsenic then could be blocking the MyoD and E-
box transcriptional complex by interfering post-translational modifications of MyoD.  
Histone acetyltransferases (HATs) and histone deacetylases (HDACs) both 
interact with MyoD, switching it from a repressor state, to an activator (Berkes and 
Tapscott, 2005). HATs transfer an acetyl group from acetyl-coA, which has been shown 
to increase during the differentiation stage of myogenesis (Polesskaya et al., 2001), which 
then causes the transfer of histones H2A/H2B from DNA to chaperone proteins (Ito et al., 
2000). This then allows transcription factors, like MyoD, to get to the DNA and bind with 
the E-box forming the transcriptional complex (Bergstrom et al., 2002). In myotubes, the 
complex formed includes MyoD, and HAT-proteins p300 and PCAF which then allows 
MyoD to stably bind to the E-box of additional myogenic genes (Puri et al., 1997).  
Arsenic then could be interfering with HATs, and stopping the formation of these 
complexes. Without MyoD translocation to the nucleus and binding to the E-box, no 
further signal transduction is occurring, which then results in the decrease in the 
differentiation of the precursors into myotubes and sensory neurons. 
In conclusion, our results indicate that As, MMA III, and DMA III all suppresses 
skeletal muscle and sensory neuron formation by targeting NPBS cells during 
embryogenesis in P19 mouse embryonic stem cells. MMA III was shown to be the most 
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toxic to the cells, followed by DMA III, and sodium arsenite. The metabolites toxicity is 
of great concern due to the fact that they are increased during pregnancy and can cause 
miscarriages, and many detrimental neurological and physical conditions later on in life. 
This study also sheds light on some of the temporal and spatial aspects on the neurogenic 
and myogenic signals involved after exposure to arsenic and its metabolites. In addition, 
it provides insight on how exposure to arsenic and its metabolites can affect 
differentiation of skeletal muscle and sensory neurons, and shows the effectiveness of 
using embryonic stem cells to study the determination of cell fates. 
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Figure 1.  Arsenic decreases Pax3 intensity, and Msx1 and MyoD nuclear 
localization in day 2 embryoid bodies 
After exposure to 0, 0.1, and 0.5 µM arsenic for two days, embryoid bodies were fixed, 
embedded, and stained for transcription factor expression.  Representative images are 
shown (A; n=3 per group).  Intensity values were averaged, and are presented as relative 
fluorescence after normalization to the control group + standard deviation (B).  Nuclear 
localization was determined by placing a 50µm x 100µm grid on each image. The cells 
(n=100) where the counted and examined for nuclear localization of each marker. 
Nuclear localization is presented as % nuclear localization + standard deviation (C).  
Statistical differences were determined by ANOVA followed by Tukey’s (*; p<0.05 ).  
Although myogenin and NeuroD1 expression were examined, neither of the transcription 
factors are expressed on day 2. 
 
A. 
B. 
  
 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 0.1M As 0.5M As 
Msx1 
 Sox10 
 Pax3 
Msx1+ 
MyoD 
MyoD 
A. 
  
 45 
 
 
Figure 2.  Arsenic decreases Sox10 intensity, and MyoD nuclear localization in day 3 
embryoid bodies 
After exposure to 0, 0.1, and 0.5 µM arsenic for three days, embryoid bodies were fixed, 
embedded, and stained for Msx1, MyoD, Pax3, and Sox10 expression.  Representative 
images are shown (A; n=3 per group).  Intensity values (B) and nuclear localization (C) 
were calculated as in Figure 1. Statistical differences were determined by ANOVA 
followed by Tukey’s (*; p<0.05 ). 
A. 
B. 
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Figure 3.  Arsenic decreases NeuroD1 intensity, and MyoD and NeuroD1 nuclear 
localization in day 4 embryoid bodies 
After exposure to 0, 0.1, and 0.5 µM arsenic for four days, embryoid bodies were fixed, 
embedded, and stained for transcription factor expression.  Representative images are 
shown (A; n=3 per group).  Intensity values (B) and nuclear localization (C) were 
calculated as in Figure 1. Statistical differences were determined by ANOVA followed 
by Tukey’s (*; p<0.05 ). 
A. 
B. 
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Figure 4.  Arsenic decreases NeuroD1 intensity and nuclear localization in day 5 
embryoid bodies 
After exposure to 0, 0.1, and 0.5 µM arsenic for five days, embryoid bodies were fixed, 
embedded, and stained for Msx1, MyoD, Myogenin, Pax3, Sox10, and NeuroD1 
expression.  Representative images are shown (A; n=3 per group).  Intensity values (B) 
and nuclear localization (C) were calculated as in Figure 1. Statistical differences were 
determined by ANOVA followed by Tukey’s (*; p<0.05 ).  
A. 
B. 
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Figure 5.  MMA(III) MyoD and Pax3 nuclear localization in day 3 embryoid bodies 
After exposure to 0, 0.01, and 0.05 µM MMA for three days, embryoid bodies were 
fixed, embedded, and stained for transcription factor expression. (Representative images 
are shown in Figure S1, n=3 per group).  Intensity values (A) and nuclear localization (B) 
were calculated as in Figure 1. Statistical differences were determined by ANOVA 
followed by Tukey’s (*; p<0.05 ). 
A. 
B. 
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Figure 6.  MMA(III) decreases MyoD and Pax3 nuclear localization in day 5 
embryoid bodies 
After exposure to 0, 0.01, and 0.05 µM MMA for five days, embryoid bodies were fixed, 
embedded, and stained for Msx1, MyoD, Myogenin, Pax3, Sox10, and NeuroD1 
expression.  (Representative images are shown in Figure S2, n=3 per group). Intensity 
values (A) and nuclear localization (B) were calculated as in Figure 1. Statistical 
differences were determined by ANOVA followed by Tukey’s (*; p<0.05 ) 
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Figure 7. DMA(III) decreases MyoD nuclear localization in day 3 embryoid bodies 
After exposure to 0, 0.001, and 0.005 µM DMA for three days, embryoid bodies were 
fixed, embedded, and stained for transcription factor expression. (Representative images 
are shown in Figure S3, n=3 per group).  Intensity values (A) and nuclear localization (B) 
were calculated as in Figure 1. Statistical differences were determined by ANOVA 
followed by Tukey’s (*; p<0.05 ). 
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Figure 8. DMA(III) decreases MyoD and NeuroD1 nuclear localization in day 5 
embryoid bodies 
After exposure to 0, 0.001, and 0.005 µM DMA for five days, embryoid bodies were 
fixed, embedded, and stained for Msx1, MyoD, Myogenin, Pax3, Sox10, and NeuroD1 
expression. (Representative images are shown in Figure S4, n=3 per group).  Intensity 
values (A) and nuclear localization (B) were calculated as in Figure 1. Statistical 
differences were determined by ANOVA followed by Tukey’s (*; p<0.05 ). 
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Table 1.  Time course of transcription factor expression and nuclear translocation in 
P19 cell-derived embryoid bodies.   
 Expression (days)
a
  Nuclear localization (days)
b
 
 2 3 4 5  2 3 4 5 
Neural lineage          
Pax3 
(neural plate border cells) 
++ ++ ++ ++  +++ ++++ ++++ +++ 
Sox10 
(neural crest progenitors) 
++ ++ ++ ++  + + + + 
NeuroD1 
(neural crest cells) 
- - +++ ++  - - ++++ +++ 
Muscle lineage          
Msx1 
(neural plate border cells) 
+ +++ +++ ++  + + + + 
MyoD 
(myogenic progenitor) ++ ++ ++ ++  + ++ ++++ 
+++
+ 
Myogenin 
(myocytes) 
- - - +  - - - + 
aRelative expression values; “ –“:  not expressed; “”+”:  low expression; “++”:  medium 
expression; “+++”: high expression. 
bAverage percent nuclear localization:  “ –“:  not expressed; “”+”:  1-10% nuclear 
localization; “++”:  11-50% nuclear localization; “+++”: 51-70% nuclear localization; 
“++++”:  >71% nuclear localization. 
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Table 2.  Changes in overall transcription factor expression after exposure to 0.1 
and 0.5 µM arsenic during P19 cell differentiation.   
 Day 2 Day 3 Day 4 Day 5 
Neural Lineage     
Pax3 
(neural plate border 
cells) 
    
Sox10 
(neural crest 
progenitors) 
    
NeuroD1 
(neural crest cells) 
X X   
Muscle Lineage     
Msx1 
(neural plate border 
cells) 
    
MyoD 
(myogenic progenitor) 
    
Myogenin  
(myocytes) 
X X X  
 
An arrow indicates reduced expression, a dash indicates no change in expression, and an 
X indicates that the TF was not expressed on that day. 
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Table 3.  Changes in overall transcription factor expression after exposure to 
monomethylarsonous acid (MMA) and dimethylarsinous acid (DMA) during P19 
cell differentiation.   
 Day 3 Day 5 
 iAs MMA DMA iAs MMA DMA 
Neural 
Lineage 
      
Pax3  
(neural plate 
border cells) 
      
Sox10  
(neural crest 
progenitors) 
      
NeuroD1  
(neural crest 
cells) 
X X X    
Muscle 
Lineage 
      
Msx1  
(neural plate 
border cells) 
      
MyoD  
(myogenic 
progenitor) 
      
Myogenin 
(myocytes) 
X X X    
An arrow indicates reduced expression, a dash indicates no change in expression, and an 
X indicates that the TF was not expressed on that day. 
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Table 4.  Changes in the nuclear translocation of transcription factors after 
exposure to monomethylarsonous acid (MMA) and dimethylarsinous acid (DMA) 
during P19 cell differentiation.   
 Day 3 Day 5 
 iAs MMA DMA iAs MMA DMA 
Neural 
Lineage 
      
Pax3  
(neural plate 
border cells) 
      
Sox10  
(neural crest 
progenitors) 
      
NeuroD1  
(neural crest 
cells) 
X X X    
Muscle 
Lineage 
      
Msx1  
(neural plate 
border cells) 
      
MyoD  
(myogenic 
progenitor) 
      
Myogenin 
(myocytes) 
X X X    
An arrow indicates reduced expression, a dash indicates no change in expression, and an 
X indicates that the TF was not expressed on that day. 
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Table 5.  Changes in the nuclear translocation of transcription factors after 
exposure to monomethylarsonous acid (MMA) and dimethylarsinous acid (DMA) 
during P19 cell differentiation.   
 MMA DMA 
 Day 3 Day 5 Day 3 Day 5 
Neural Lineage     
Pax3  
(neural plate border 
cells) 
    
Sox10  
(neural crest 
progenitors) 
    
NeuroD1  
(neural crest cells) 
X  X  
Muscle Lineage     
Msx1  
(neural plate border 
cells) 
    
MyoD  
(myogenic 
progenitor) 
    
Myogenin 
(myocytes) 
X  X  
An arrow indicates reduced expression, a dash indicates no change in expression, and an 
X indicates that the TF was not expressed on that day. 
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Supplementary Figure 1.  MMA (III) decreases Msx1, MyoD, Pax3, Sox10 intensity 
in day 3 embryoid bodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
Control 0.01M As 0.05M As 
Msx1 
MyoD 
 Pax3 
 Sox10 
Msx1 + 
MyoD  
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Supplementary Figure 2.  MMA(III) decreases Pax3, Sox10 and NeuroD1 intensity 
in day 5 embryoid bodies. 
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Supplementary Figure 3. DMA(III) caused no marked decreases in transcription 
factor intensity in day 3 embryoid bodies. 
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Supplementary Figure 4. DMA(III) decreases Msx1, MyoD, Myogenin, Sox10 and 
NeuroD1 intensity in day 5 embryoid bodies. 
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Supplementary Figure 5. Differentiating P19 cells contain arsenic 
methyltransferase. 
 
Arsenic methyltransferase (As3MT) transcript levels in differentiating P19 cells, which 
suggests that they are fully capable of methylating arsenic. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day 0    Day 2   Day 5 
As3MT 
18S rRNA 
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CHAPTER THREE 
 
CONCLUSION 
 
Even with our knowledge that chronic arsenic exposure has a negative effect on 
development, the exact mechanisms of how arsenic causes these undesired 
developmental outcomes is still poorly understood. We already knew that arsenic disrupts 
embryoid body formation (Stummann et al., 2008), myogenesis (Garcia-Chavez et al., 
2007), and neurogenesis (Piao et al., 2005; Wang et al., 2010), but hopefully my study 
has now shed some light on the temporal and spatial aspects of the NPBS signals 
involved during neurogenesis and myogenesis. It appears that arsenic targets the neural 
plate border specifier cells.  Since these cells arise early during embryogenesis and give 
rise to cell types such as the neural crest (Hong and Saint-Jeannet, 2007; Le Douarin and 
Kalcheim, 1999), this targeting could account for why arsenic can impact structures as 
diverse as the elements of the craniofacial skeleton, muscle progenitors, melanocytes, and 
parts of the nervous system and glia. 
This study has also demonstrated the harmful effects that arsenic and its 
metabolites can exert on cells and the usefulness of using cell lines to examine cell fates. 
It is particularly alarming that arsenic’s metabolites MMA III and DMA III can target the 
NPBS cells at much lower concentrations than arsenic itself. With these metabolites 
increasing during pregnancy (Davis et al., 2012) this is very worrying for any expecting 
parents, especially those who live in areas with very high levels of arsenic contamination 
in their water supply including areas in Mexico, Chile, India, and Bangladesh. Some of 
the wells in these countries can have to 500 µg/L (Desbarats et al., 2014), which is 50 
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times the limit set by the World Health Organization. In addition, Chilean pregnant 
women whose drinking water had arsenic levels around 40 μg/L had increased urinary 
arsenic levels (Hopenhayn et al., 2003). By gestational week 36 urinary arsenic levels had 
increased to 54 μg/L and urinary DMA levels had increased to 47 μg/L (Hopenhayn et 
al., 2003). Studies in Matlab, Bangladesh have shown urinary arsenic levels up to 89µg/L 
as early as gestational week 8 in pregnant women exposed to water with >50 µg/L arsenic 
(Rahman et al., 2010). These urinary arsenic levels translate to an odds ratio for a 
spontaneous abortion of 1.31 for women <20, but for women >40 years old, the odds 
ratio jumps to 4.5 (Rahman et. al, 2010).   
In addition to a rise in urinary arsenic levels, blood arsenic levels have been to 
increase as well. In Argentina, pregnant women whose water contained 200 µg/L of 
arsenic had 9 µg/L of arsenic in their cord blood, which was almost as high as the 
maternal blood which contained 11 µg/L of arsenic (Concha et al., 1998). Another study 
had similar findings. In Bangladesh, pregnant women who were exposed to water 
containing 90.5 µg/L had cord blood arsenic levels of 23.1 µg/L, with over 31% of it 
being in the form of MMA (Hall et al., 2007).  Both of these studies show that arsenic is 
easily transported from the placenta to the fetus. This was confirmed when looking at the 
placental arsenic levels and the baby’s urine. There was 34µg/kg of arsenic in the 
placenta late in gestation in exposed women, but only 7µg/kg for non-exposed women 
(Concha et al. 1998). Regarding the baby’s urine, it was found that it contained on 
average 80µg/L of arsenic during the first two days, and was still elevated as high as 
30µg/L at 4.5 months of age (Concha et al., 1998). This is particularly worrying due to 
  
 73 
the fact that in our study we found that levels as low as 0.005µM DMA, or 0.375µg/L has 
adverse effects on cells in vitro. 
Research now needs to focus on identifying exactly what thresholds these harmful 
effects start to appear. In addition, much more resources need to be dedicated to looking 
at arsenic’s metabolites, and carrying our more in vivo studies examining what diseases 
appear at certain thresholds. We aren’t sure at exactly what threshold things like 
cutaneous lesions, Blackfoot disease, and cancer start to appear. Many genetic factors 
including methylation and metabolism efficiency comes into play. It has been shown that 
the rate of excretion of As and its metabolites increases as methylation efficiency 
increases (Vahter, 1999). However, methylation efficiency is known to vary between 
children and adults, with women having much higher methylation rates than men, 
especially during pregnancy (Vahter, 1999).  
However, what we do know is that arsenic exposure around the world is an 
epidemic. Even in the United States over 4 million people have harmful levels of arsenic 
in their drinking water (Ambrosio et al., 2014). People in countries such as Bangladesh, 
India, Chile and Mexico are in need of help. This help could be as simple as education 
about arsenic contamination, painting contaminated wells red and non-contaminated ones 
green, and even installing filtering systems to remove the arsenic from the water. It is 
also very important, even in the United States, to keep on monitoring arsenic levels in our 
food and drinks to help establish more robust safety standards. 
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